Literature DB >> 8097490

T-cell activation. V. Anti-major histocompatibility complex class I antibody-induced activation and clonal abortion in Jurkat T-leukaemic cells.

M H Claesson1, S Dissing, T Tscherning, C Geisler.   

Abstract

We have studied activation-induced changes in intracellular calcium [Ca2+]i, interleukin-2 (IL-2) secretion, and clonal abortion of the human leukaemic T-cell line Jurkat and three T-cell receptor (TcR)/CD3 receptor negative clones deficient for the TcR alpha, TcR beta and CD3 gamma chains respectively, as well as three transfectant clones reconstituted with the appropriate TcR/CD3 cDNA. For activation, the cells were exposed to anti-TcR/CD3, anti-CD2 and anti-major histocompatibility complex (anti-MHC) class I monoclonal antibodies (mAb) respectively. Cellular activation by these mAb leading to an increased IL-2 secretion was preceded by a rise in [Ca2+]i and was relatively dependent on the expression of the a TcR/CD3 complex. In contrast, anti-MHC class I mAb-induced clonal abortion in Jurkat T cells may occur without previous fluctuations in [Ca2+]i and appeared to be independent of TcR/CD3 expression. The present observation suggest the existence of different secondary messenger systems operating in Jurkat cells following activation via the TcR/CD3, CD2 and the MHC class I pathways, respectively.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097490      PMCID: PMC1421850     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  18 in total

Review 1.  Molecular events mediating T cell activation.

Authors:  A Altman; K M Coggeshall; T Mustelin
Journal:  Adv Immunol       Date:  1990       Impact factor: 3.543

2.  Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes.

Authors:  J A Ledbetter; C H June; L S Grosmaire; P S Rabinovitch
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

3.  Patterns of costimulation of T cell clones by cross-linking CD3, CD4/CD8, and class I MHC molecules.

Authors:  M C Wacholtz; S S Patel; P E Lipsky
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

4.  Characterization and expression of the human T cell receptor-T3 complex by monoclonal antibody F101.01.

Authors:  C Geisler; T Plesner; G Pallesen; K Skjødt; N Odum; J K Larsen
Journal:  Scand J Immunol       Date:  1988-06       Impact factor: 3.487

5.  Clonal suppression of HL60 and U937 cells by recombinant human leukemia inhibitory factor in combination with GM-CSF or G-CSF.

Authors:  T Maekawa; D Metcalf
Journal:  Leukemia       Date:  1989-04       Impact factor: 11.528

6.  Selection and characterization of T-cell variants lacking molecules involved in T-cell activation (T3 T-cell receptor, T44, and T11): analysis of the functional relationship among different pathways of activation.

Authors:  A Moretta; A Poggi; D Olive; C Bottino; C Fortis; G Pantaleo; L Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

Review 7.  Compound receptors in the cell membrane: ruminations from the borderland of immunology and physiology.

Authors:  M Simonsen; K Skjødt; M Crone; A Sanderson; Y Fujita-Yamaguchi; C Due; E Rønne; K Linnet; L Olsson
Journal:  Prog Allergy       Date:  1985

8.  T cell activation. II. Activation of human T lymphoma cells by cross-linking of their MHC class I antigens.

Authors:  S Dissing; C Geisler; B Rubin; T Plesner; M H Claesson
Journal:  Cell Immunol       Date:  1990-03       Impact factor: 4.868

9.  T-cell activation. I. Evidence for a functional linkage between class I MHC antigens and the Tc-Ti complex.

Authors:  P Brams; M H Claesson
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

10.  Expression of a functional CD3-Ti antigen/MHC receptor in the absence of surface CD2. Analysis with clonal Jurkat cell mutants.

Authors:  P Moingeon; A Alcover; L K Clayton; H C Chang; C Transy; E L Reinherz
Journal:  J Exp Med       Date:  1988-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.